Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Cerevel Therapeutics Holdings, Inc. Common Stock (CERE)

Pharmaceutical Preparations

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

222 JACOBS STREET, SUITE 200
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/28/2020

Market Cap

8,191,487,560

Shares Outstanding

181,360,000

Weighted SO

181,427,590

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

RNA --.--%

RVMD --.--%

DAWN --.--%

SWTX --.--%

VTYX --.--%

NUVL --.--%

TVTX --.--%

GPCR --.--%

GLUE --.--%

Beta

1.4070

Last Div

0.0000

Range

19.59-44.99

Chg

0.3300

Avg Vol

2056487

Mkt Cap

8191487560

Exch

NASDAQ

Country

US

Phone

844 304 2048

DCF Diff

41.8118

DCF

3.1482

Div Yield

0.0000

P/S

993.3892

EV Multiple

-18.0678

P/FV

14.4657

Div Yield %

0.0000

P/E

-17.7324

PEG

1.1754

Payout

0.0000

Current Ratio

10.2204

Quick Ratio

10.1224

Cash Ratio

3.8100

DSO

219.6817

DIO

514.5707

Op Cycle

734.2524

DPO

676.6265

CCC

57.6259

Gross Margin

0.2909

Op Margin

-59.4676

Pretax Margin

-55.7740

Net Margin

-55.8414

Eff Tax Rate

-0.0012

ROA

-0.4085

ROE

-0.9894

ROCE

-0.4700

NI/EBT

1.0012

EBT/EBIT

0.9379

EBIT/Rev

-59.4676

Debt Ratio

0.3267

D/E

0.6525

LT Debt/Cap

0.3926

Total Debt/Cap

0.3949

Int Coverage

-46.3356

CF/Debt

-0.9966

Equity Multi

1.9972

Rec Turnover

1.6615

Pay Turnover

0.5394

Inv Turnover

0.7093

FA Turnover

0.1849

Asset Turnover

0.0073

OCF/Share

-2.0211

FCF/Share

-2.0417

Cash/Share

4.6599

OCF/Sales

-44.5121

FCF/OCF

1.0102

CF Coverage

-0.9966

ST Coverage

-104.4230

CapEx Coverage

-98.0622

Div&CapEx Cov

-98.0622

P/BV

14.4657

P/B

14.4657

P/S

993.3892

P/E

-17.7324

P/FCF

-22.0920

P/OCF

-22.2457

P/CF

-22.2457

PEG

1.1754

P/S

993.3892

EV Multiple

-18.0678

P/FV

14.4657

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jan 07, 07:33 Is AbbVie Stock a Buy Now? The Motley Fool Jan 07, 07:33 Is AbbVie Stock a Buy Now? Benzinga Dec 28, 12:00 JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know Zacks Investment Research Dec 26, 11:20 Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers MarketWatch Dec 22, 09:20 Karuna Therapeutics' stock hits record territory after Bristol Myers' $14 billion buyout deal Benzinga Dec 22, 07:33 Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday The Motley Fool Dec 10, 07:45 4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December The Motley Fool Dec 10, 07:45 4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December The Motley Fool Dec 10, 05:51 AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool Dec 10, 05:51 AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool Dec 08, 05:38 AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? Benzinga Dec 07, 15:19 AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals MarketWatch Dec 07, 08:34 There's a new dynamic heading into payrolls report, Goldman trading expert says Benzinga Dec 07, 07:41 Datadog To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Thursday MarketWatch Dec 07, 06:41 There's a new dynamic heading into payrolls report, Goldman trading expert says Benzinga Dec 06, 17:14 Why Cerevel Therapeutics Holdings Is Moving After-Hours GlobeNewswire Inc. Nov 29, 06:30 Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease GlobeNewswire Inc. Nov 01, 06:30 Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Revenue Product Segmentation